<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04202211</url>
  </required_header>
  <id_info>
    <org_study_id>H19-03882</org_study_id>
    <nct_id>NCT04202211</nct_id>
  </id_info>
  <brief_title>FMT for Remission of Active Ulcerative Colitis in Adults</brief_title>
  <official_title>A Randomized Double-blind, Placebo-controlled Trial of Lyophilized Fecal Microbiota Transplantation for the Induction of Remission in Adults With Active Ulcerative Colitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of British Columbia</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Crohn's and Colitis Canada</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Vancouver Island Health Authority</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of British Columbia</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The goal of this study is to establish the safety and effectiveness of lyophilized (LYO)
      fecal microbiota transplant (FMT) for treating ulcerative colitis (UC) in adults. This is
      multi-site, randomized double-blind, placebo-controlled trial. UC patients with active
      disease will be recruited at three Canadian centres and the study involves 3 treatment arms:

        1. FMT oral capsules + placebo enema

        2. placebo oral capsules + placebo enema

        3. FMT oral capsules and FMT enema The primary outcome is achievement of remission of UC;
           the efficacy of LYO-FMT in achieving remission of active ulcerative colitis in adults
           will be evaluated.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">February 2020</start_date>
  <completion_date type="Anticipated">February 2025</completion_date>
  <primary_completion_date type="Anticipated">May 2023</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>145 active UC participants will be randomized to one of the three treatment groups in 1:2:2 randomization ratio</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
    <masking_description>Gastroenterologists performing flexible sigmoidoscopes will remain blinded to participant's treatment. One unblinded nurse will administer the FMT enema.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Remission of UC</measure>
    <time_frame>9 weeks following receipt of LYO-FMT</time_frame>
    <description>achievement of remission of UC as defined by Mayo score ≤ 2 AND Mayo endoscopic score of ≤ 1</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence/absence of adverse events upon treatment with LYO-FMT [safety and tolerability]</measure>
    <time_frame>up to 5 years post-FMT</time_frame>
    <description>Safety of LYO-FMT in patients with active UC as determined by absence of adverse events</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>UC disease progression</measure>
    <time_frame>immediately after FMT (study) treatment period up to 5 years post-FMT</time_frame>
    <description>Determine progression of UC based on development of any of the following:
Clinical flare of UC requiring hospitalization up to 3 months post-FMT
Increase in dosages of current UC specific medications up to 3 months' post FMT
Time to colectomy for UC flare up to 12 months' post FMT
Time to death directly attributable to UC up to 5 years post FMT
Improvement in clinical response defined by decrease in Partial Mayo score by ≥ 3 points from pre to post LYO-FMT.
Improvement in patient-reported health related QoL using Valuation of Lost Productivity and (VOLP) and RAND VR12 measured at pre and at 5 weeks, 12 and 24 weeks following LYO-FMT and annually for 5 years
Reduction in biologic inflammatory markers (serum c-reactive protein (CRP) and fecal calprotectin) from pre to post LYO-FMT</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">145</enrollment>
  <condition>Ulcerative Colitis</condition>
  <condition>Inflammatory Bowel Diseases</condition>
  <arm_group>
    <arm_group_label>Placebo oral &amp; enema</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>twice weekly x 8 weeks: 10 placebo oral capsules + placebo enema</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LYO-FMT oral + placebo enema</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>twice weekly x 8 weeks: 10 LYO-FMT oral capsules + 1 placebo enema</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LYO-FMT oral + LYO-FMT enema</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>twice weekly x 8 weeks: 10 LYO-FMT oral capsules + 1 LYO-FMT enema</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>FMT oral</intervention_name>
    <description>lyophilized FMT given orally (10 capsules) twice weekly for total of 8 weeks</description>
    <arm_group_label>LYO-FMT oral + LYO-FMT enema</arm_group_label>
    <arm_group_label>LYO-FMT oral + placebo enema</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>FMT enema</intervention_name>
    <description>lyophilized FMT given via enema (1) twice weekly for total of 8 weeks</description>
    <arm_group_label>LYO-FMT oral + LYO-FMT enema</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo oral</intervention_name>
    <description>placebo given orally (10 capsules) twice weekly for total of 8 weeks</description>
    <arm_group_label>Placebo oral &amp; enema</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo enema</intervention_name>
    <description>placebo given via enema (1) twice weekly for total of 8 weeks</description>
    <arm_group_label>LYO-FMT oral + placebo enema</arm_group_label>
    <arm_group_label>Placebo oral &amp; enema</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Able to provide informed consent.

          -  Willing and able to comply with all the required trial procedures

          -  Active ulcerative colitis as defined by Mayo score &gt; 3 AND Mayo endoscopic sub-score &gt;
             1 (within 30 days before enrollment, or at baseline)

        Exclusion Criteria:

          -  Planned or actively taking another investigational product

          -  Abdominal surgery within the past 60 days

          -  Patients with neutropenia with absolute neutrophil count &lt;0.5 x 109/L at - Evidence of
             toxic megacolon or gastrointestinal perforation on imaging

          -  Peripheral white blood cell count &gt; 35.0 x 109/L at enrollment AND temperature &gt;
             38.0oC

          -  Active infectious diarrhea at the time of enrolment

          -  Increase in medical therapy for UC within 3 months of enrollment. Continued treatment
             with stable dose of 5-ASA, azathioprine, 6-mercaptopurine, cyclosporine, prednisone
             and/or anti- TNF agents for at least 3 months of is allowed

          -  Severe UC requiring hospitalization at the time of enrolment

          -  Pregnant or lactating

          -  History of anaphylaxis to any food

          -  Requiring oral and/or intravenous systemic antibiotic therapy at the time of study
             enrolment

          -  Unwilling to discontinue probiotic (yogurt is allowed)

          -  Severe underlying disease such that the patient is not expected to survive for at
             least 30 days.

          -  Any condition that in the opinion of the investigator that would pose harm to the
             participant or the research staff for the potential participant to take part in the
             trial
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ted Steiner, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of British Columbia</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Laura Oliveira</last_name>
    <phone>604 875 4111</phone>
    <phone_ext>64164</phone_ext>
    <email>laura.oliveira@ubc.ca</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of Alberta Hospital</name>
      <address>
        <city>Edmonton</city>
        <state>Alberta</state>
        <zip>T6G 2B7</zip>
        <country>Canada</country>
      </address>
    </facility>
    <contact>
      <last_name>Rose Franz</last_name>
      <email>Rose.Franz@albertahealthservices.ca</email>
    </contact>
    <investigator>
      <last_name>Dina Kao, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Vancouver General Hospital</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V5Z 1M9</zip>
        <country>Canada</country>
      </address>
    </facility>
    <contact>
      <last_name>Laura Oliveira</last_name>
      <phone>604 875 4111</phone>
      <phone_ext>64164</phone_ext>
      <email>laura.oliveira@ubc.ca</email>
    </contact>
    <investigator>
      <last_name>Ted Steiner, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Royal Jubilee Hospital</name>
      <address>
        <city>Victoria</city>
        <state>British Columbia</state>
        <zip>V8R 1J8</zip>
        <country>Canada</country>
      </address>
    </facility>
    <contact>
      <last_name>Peyman Goldeh</last_name>
      <email>Peyman.Goldeh@VIHA.CA</email>
    </contact>
    <investigator>
      <last_name>Christine Lee, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>December 2019</verification_date>
  <study_first_submitted>December 13, 2019</study_first_submitted>
  <study_first_submitted_qc>December 13, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">December 17, 2019</study_first_posted>
  <last_update_submitted>December 16, 2019</last_update_submitted>
  <last_update_submitted_qc>December 16, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">December 18, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of British Columbia</investigator_affiliation>
    <investigator_full_name>Theodore Steiner</investigator_full_name>
    <investigator_title>MD, Professor</investigator_title>
  </responsible_party>
  <keyword>ulcerative colitis</keyword>
  <keyword>Fecal Microbiota transplant</keyword>
  <keyword>FMT</keyword>
  <keyword>Inflammatory bowel disease</keyword>
  <keyword>IBD</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colitis</mesh_term>
    <mesh_term>Colitis, Ulcerative</mesh_term>
    <mesh_term>Intestinal Diseases</mesh_term>
    <mesh_term>Inflammatory Bowel Diseases</mesh_term>
    <mesh_term>Ulcer</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

